Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
|
|
Akero Therapeutics, Inc. (AKRO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/10/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 10/04/2023 |
4
| Cheng Andrew (President and CEO) has filed a Form 4 on Akero Therapeutics, Inc.|
Txns:
| Sold 8,868 shares
@ $46.057, valued at
$408.4k
Sold 5,300 shares
@ $46.8836, valued at
$248.5k
Sold 2,662 shares
@ $48.5632, valued at
$129.3k
Sold 1,700 shares
@ $49.7059, valued at
$84.5k
Sold 6,470 shares
@ $50.5619, valued at
$327.1k
Exercised 25,000 options to buy
@ $6.36, valued at
$159k
|
|
| 10/04/2023 |
4
| Young Jonathan (COO) has filed a Form 4 on Akero Therapeutics, Inc.|
Txns:
| Sold 490 shares
@ $51.1, valued at
$25k
Exercised 490 options to buy
@ $21.1, valued at
$10.3k
|
|
| 10/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 10/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/11/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
4
| Graham G. Walmsley (Director) has filed a Form 4 on Akero Therapeutics, Inc.|
Txns:
| Bought 25,000 shares
@ $42.059, valued at
$1.1M
|
|
| 08/03/2023 |
4
| Cheng Andrew (President and CEO) has filed a Form 4 on Akero Therapeutics, Inc.|
Txns:
| Sold 13,679 shares
@ $42.8514, valued at
$586.2k
Sold 11,321 shares
@ $43.5211, valued at
$492.7k
Exercised 25,000 options to buy
@ $6.36, valued at
$159k
|
|
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/06/2023 |
4
| Cheng Andrew (President and CEO) has filed a Form 4 on Akero Therapeutics, Inc.|
Txns:
| Sold 18,730 shares
@ $44.6606, valued at
$836.5k
Sold 5,051 shares
@ $45.3615, valued at
$229.1k
Sold 1,219 shares
@ $46.2896, valued at
$56.4k
Exercised 25,000 options to buy
@ $6.36, valued at
$159k
|
|
| 07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/15/2023 |
4
| White William Richard (CFO) has filed a Form 4 on Akero Therapeutics, Inc.|
Txns:
| Sold 606 shares
@ $55.16, valued at
$33.4k
|
|
| 06/15/2023 |
4
| Cheng Andrew (President & CEO) has filed a Form 4 on Akero Therapeutics, Inc.|
Txns:
| Sold 1,613 shares
@ $55.16, valued at
$89k
|
|
| 06/15/2023 |
4
| Rolph Timothy (Chief Scientific Officer) has filed a Form 4 on Akero Therapeutics, Inc.|
Txns:
| Sold 509 shares
@ $55.16, valued at
$28.1k
|
|
| 06/15/2023 |
4
| Young Jonathan (COO) has filed a Form 4 on Akero Therapeutics, Inc.|
Txns:
| Sold 538 shares
@ $55.16, valued at
$29.7k
|
|
| 06/15/2023 |
4
| Yale Catriona (Chief Development Officer) has filed a Form 4 on Akero Therapeutics, Inc.|
Txns:
| Sold 591 shares
@ $55.16, valued at
$32.6k
|
|
| 06/15/2023 |
4/A
| Graham G. Walmsley (Director) has filed a Form 4 on Akero Therapeutics, Inc.|
Txns:
| Bought 400,000 shares
@ $26, valued at
$10.4M
Bought 120,000 shares
@ $42, valued at
$5M
|
|
| 06/05/2023 |
4
| Cheng Andrew (President and CEO) has filed a Form 4 on Akero Therapeutics, Inc.|
Txns:
| Sold 3,914 shares
@ $44.1752, valued at
$172.9k
Sold 20,686 shares
@ $45.2562, valued at
$936.2k
Sold 400 shares
@ $45.897, valued at
$18.4k
Exercised 21,330 options to buy
@ $0.615, valued at
$13.1k
Exercised 3,670 options to buy
@ $6.36, valued at
$23.3k
|
|
| 05/23/2023 |
4
| Graham G. Walmsley (Director) has filed a Form 4 on Akero Therapeutics, Inc.|
Txns:
| Bought 400,000 shares
@ $26, valued at
$10.4M
Bought 120,000 shares
@ $42, valued at
$5M
|
|
| 05/17/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Underwriting Agreement, by and between the Company and Jefferies LLC, as representative of the several underwriters named therein",
"Opinion of Goodwin Procter LLP",
"Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock South San Francisco, CA - May 16, 2023 - Akero Therapeutics, Inc. , a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the pricing of an underwritten offering of 5,238,500 shares of its common stock at a price of $42.00 per share, before deducting underwriting discounts and commissions, for total gross proceeds of approximately $220.0 million. All of the shares to be sold in the offering are being sold by Akero Therapeutics. The financing was led by new investor General Atlantic and included existing investors Adage Capital Partners LP, Avidity Partners, Boxer Capital, Commodore Capital, Janu..." |
|
| 05/17/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/15/2023 |
8-K
| Quarterly results |
| 05/03/2023 |
4
| Cheng Andrew (President & CEO) has filed a Form 4 on Akero Therapeutics, Inc.|
Txns:
| Sold 21,523 shares
@ $45.0049, valued at
$968.6k
Sold 3,477 shares
@ $45.5045, valued at
$158.2k
Exercised 40,000 options to buy
@ $0.615, valued at
$24.6k
Exercised 25,000 options to buy
@ $0.615, valued at
$15.4k
|
|
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/05/2023 |
4
| Cheng Andrew (President & CEO) has filed a Form 4 on Akero Therapeutics, Inc.|
Txns:
| Sold 23,292 shares
@ $37.8783, valued at
$882.3k
Sold 1,708 shares
@ $38.8259, valued at
$66.3k
Exercised 25,000 options to buy
@ $0.615, valued at
$15.4k
|
|
| 04/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 03/29/2023 |
8-K
| Quarterly results |
|
|
|